Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
| Market Cap | 10.45B |
| Revenue (ttm) | 737.54M |
| Net Income (ttm) | -790.69M |
| Shares Out | 71.04M |
| EPS (ttm) | -11.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 577,932 |
| Open | 146.69 |
| Previous Close | 146.98 |
| Day's Range | 146.72 - 147.56 |
| 52-Week Range | 79.01 - 151.51 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 156.57 (+6.4%) |
| Earnings Date | Aug 8, 2022 |
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The com... [Read more...]
Financial Performance
In 2021, BHVN's revenue was $462.51 million, an increase of 626.91% compared to the previous year's $63.63 million. Losses were -$846.59 million, 10.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is 156.57, which is an increase of 6.40% from the latest price.
News
Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022.
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven ...
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migrai...
84% of people with migraine (PwM) and 92% of healthcare professionals (HCPs) agree that worsening migraine leads to poorer mental health Nearly all HCPs (93%) feel mental health impacts a PwM's ability ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, BHVN, DRE, PLD
NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo...
LARKSPUR, Calif.--(BUSINESS WIRE)-- #GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coal...
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including Fir...
- Nurtec ODT open-label extension study is the first of its kind evaluating a CGRP-targeted medication in patients who are using it as a preventive and an as-needed acute treatment for migraine - Over...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study a...
31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data Late-breaking submissions showcase new data fo...
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatme...
If approved, zavegepant nasal spray would be the only FDA-approved CGRP receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in ...
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
NEW HAVEN, Conn. , May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, SAIL
NEW YORK , May 16, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of...
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company L...
NEW YORK , May 13, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rate...
Here is why Biohaven Pharmaceuticals soared 70%
Biohaven Pharmaceuticals Holding Company Ltd. (NYSE: BHVN) was up 70% after the company and Pfizer Inc. (NYSE: PFE) entered a definitive agreement under which Pfizer would acquire the NURTEC ODT maker.
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023.
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd.
Wilmington, Delaware--(Newsfile Corp. - May 11, 2022) - Rigrodsky Law, P.A. is investigating Biohaven Pharmaceutical Holding Co. Ltd. ("Biohaven") (NYSE: BHVN) regarding possible breaches of fiduciary d...
Biohaven CEO discusses Pfizer's purchase of the company
CNBC's Jim Cramer spoke with Biohaven CEO Vlad Coric on Tuesday's episode of "Mad Money."
Pfizer deal will help expand reach of migraine pill Nurtec, Biohaven CEO says
"We have to bring the modern day, novel therapies to those patients, and Pfizer really is the best company to build upon our work," Coric said.
SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.
NEW YORK , May 10, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Lt...
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer. The post Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
Why Biohaven Pharmaceutical Stock Soared Today
An industry titan wants to buy the biotech for a whopping $11.6 billion.